120 related articles for article (PubMed ID: 7710989)
1. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up.
Hupperets P; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten H; Jager J; de Jong J; Beex L
Ann Oncol; 1995 Jan; 6(1):90-1. PubMed ID: 7710989
[No Abstract] [Full Text] [Related]
2. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients.
Hupperets PS; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten HC; Jager J; Smeets J; de Jong J
Ann Oncol; 1993 Apr; 4(4):295-301. PubMed ID: 8518219
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
Falkson CI; Falkson G; Falkson CB; Falkson HC
Oncology; 1992; 49(6):418-21. PubMed ID: 1465278
[TBL] [Abstract][Full Text] [Related]
4. [Two cases of advanced breast cancer effectively treated with chemoendocrine therapy and radiotherapy].
Kimura M; Hagiwara S; Hirose K; Shimokawa Y; Iwai K; Uemura K
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2505-8. PubMed ID: 7944499
[TBL] [Abstract][Full Text] [Related]
5. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
[TBL] [Abstract][Full Text] [Related]
6. [Medroxyprogesterone acetate for treatment of advanced breast cancers].
Mitsuyama S; Anan K
Nihon Rinsho; 2000 Apr; 58 Suppl():317-21. PubMed ID: 11026012
[No Abstract] [Full Text] [Related]
7. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer.
Tominaga T; Abe O; Ohshima A; Hayasaka H; Uchino J; Abe R; Enomoto K; Izuo M; Watanabe H; Takatani O
Eur J Cancer; 1994; 30A(7):959-64. PubMed ID: 7946592
[TBL] [Abstract][Full Text] [Related]
8. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
9. [A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Maruyama S; Okumoto T; Kawasaki K; Ino H; Kanaya Y; Otani J; Yokoyama N; Soda M
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2235-8. PubMed ID: 11142168
[TBL] [Abstract][Full Text] [Related]
10. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer.
Gupta P; Bijlani L; Rath GK; Misra A; Mishra MC; Shukla NK; Kriplani A; Kapur BM
Jpn J Surg; 1991 Nov; 21(6):637-42. PubMed ID: 1787609
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
[TBL] [Abstract][Full Text] [Related]
14. [A case of advanced breast cancer that responded remarkably to chemotherapy].
Watanabe Y; Kaiga T; Ueda T; Fujii M
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2113-6. PubMed ID: 11103244
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
16. [Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients].
Toi M; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1994 Sep; 21(12):2057-60. PubMed ID: 8085859
[No Abstract] [Full Text] [Related]
17. [Comparative evaluation of the effectiveness of induction chemotherapy using the Cooper, FAC and FAC + MPA protocols in patients with locally advanced breast cancer].
Pawlicki M; Brandys A; Zuchowska B
Nowotwory; 1986; 36(2):124-9. PubMed ID: 2947046
[No Abstract] [Full Text] [Related]
18. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
Abe O; Asaishi K; Izuo M; Enomoto K; Koyama H; Tominaga T; Nomura Y; Ohshima A; Aoki N; Tsukada T
Surg Today; 1995; 25(8):701-10. PubMed ID: 8520164
[TBL] [Abstract][Full Text] [Related]
19. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
20. How to improve adjuvant treatment results in postmenopausal patients.
Mouridsen HT
Recent Results Cancer Res; 1989; 115():144-52. PubMed ID: 2533698
[No Abstract] [Full Text] [Related]
[Next] [New Search]
